Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients

Holger Lawall1*, Ralph Oberacker2, Claudia Zemmrich3, Peter Bramlage3, Curt Diehm2 and Sebastian M Schellong4

Abstract

Background: Data on prevalence rates of venous thromboembolism (VTE) in different patient populations are scarce. Most studies on this topic focus on older patients or patients with malignancies, immobilization or thrombophilia. Less is known about the VTE risk profile of non-surgical patients presenting with a variety of medical diseases differing in severity. Aim of the present study was to investigate VTE prevalence in a prospective cohort study of ambulatory medical intensive care unit patients within 24 h after acute admission.

Methods: Prospective cohort study of 102 consecutive patients after acute admission to medical intensive care unit. Ultrasound compression sonography, APACHE-II-Scoring and laboratory examination was performed within 24 hours after admission. Possible determinants of a high risk of VTE were examined. In all patients with a confirmed diagnosis of DVT or suspicion of PE thoracic computer tomography (CT) was performed.

Results: VTE was found in 7.8% out of 102 of patients, mean APACHE-II-Score was 14 (mortality risk of about 15%). Thrombus location was femoropopliteal in 5 patients, iliacal in 2 and peroneal in 1 patient. Five VTE patients had concomitant PE (62.5% of VTE, 4.9% of all patients). No predictors of prevalent VTE were identified from univariable regression analysis although relative risk was high in patients with a history of smoking (RR 3.40), immobility (RR 2.50), and elevated D-Dimer levels (RR 3.49).

Conclusions: Prevalent VTE and concomitant PE were frequent in acutely admitted ICU patients.

Keywords: Prevalent VTE and concomitant PE were frequent in acutely admitted ICU patients.
DVT [8] and a reduced mortality in case of early thromboprophylaxis [9].

Among medical patients, those admitted to an Intensive Care Unit (ICU) represent a high risk population for VTE [10-13] with a higher prevalence of the aforementioned risk factors. The Asian VOICE study detected a substantial underestimation of VTE risk and non-adherence to guidelines for thromboprophylaxis in medical ICU patients [14]. Additional co-morbidities such as stroke, acute heart failure and respiratory insufficiency are highly prevalent and contribute to a worse outcome [15,16].

Reliable data on the prevalence of VTE in patients acutely admitted to a non-surgical ICU are however not available and we aimed to overcome this lack of data.

Methods

Design

This was a prospective survey of daily clinical practice with the prospective inclusion of consecutive ambulatory patients being acutely admitted to the non-surgical intensive care unit of the Karlsbad-Langensteinbach Hospital in Germany. Ethical approval of the study was not necessary due to the observational nature of the study. Patients provided written informed consent.

Patient population

Eligible patients had to have an age of at least 18 years and an APACHE-II score of at least 10 which reflects a mortality risk of about 15%. Patients with known or suspected VTE at hospital admission or prior recent hospitalization were excluded. Predominant reasons for admission were acute cardiovascular and pulmonary disorders. Among them were several myocardial infarctions, decompensated heart failure and pneumonias as the ICU focused on patients with acute cardiopulmonary diseases. No mechanically ventilated patient was included.

Variables obtained

All patients had a clinical workup at hospital admission and the following variables were obtained: reason for admission, APACHE-II score (see below), pharmacotherapy, body weight and height, smoking status, use of compression stockings, co-morbidity, presence of clinical signs of thrombosis (Payr and Homann sign, Lowenberg’s sign, cyanosis, pain, and swelling). The following lab values were determined: leukocytes, thrombocytes, erythrocytes, quick/INR value, partial thromboplastin time, fibrinogen, D-dimer and creatinine.

Detection of venous thrombo- and pulmonary embolism

Ultrasound compression sonography (ATL, HDIU 5000, Philips Medical Systems GmbH, Hamburg, Germany) was conducted in all patients within 24 hours after hospital admission according to the EXCLAIM - protocol [17]. Investigators were to scan 10 pre-defined segments of the femoral and popliteal veins including the peroneal and tibial confluens (Figure 1). For the femoral veins, static imaging was performed in the transverse plane with the patient lying supine, while compression was applied at 0.5-1.0 cm intervals along the full length of the vein. Compressed and uncompressed images were obtained at the sites. For the popliteal veins, imaging was performed with the patient in a sitting position with the legs hanging over the edge of the examination table or in case of inability to sit lying supine with the bed being tilted 30% feet downwards, and compressed and uncompressed images were obtained. In all patients with a confirmed diagnosis of DVT or suspicion of PE thoracic computer tomography (CT) was performed.

APACHE - Score

The APACHE-II (Acute Physiology And Chronic Health Evaluation) score was used to determine the prognosis (mortality) of patients [18-20]. It consists of an Acute Physiologic Score (Table 1), indicating an increased mortality risk with higher values. Age Points are added, reflecting the age dependent increase in mortality. Finally Chronic Health Score points are added for non-surgical patients with pre-existing known organ insufficiency or immunological incompetence.

Statistical methods

The analysis of data was performed with the statistical software package SPSS for Windows. Descriptive statistical analyses were performed. Frequencies were reported as means ± standard deviation (SD). Differences were tested by the Chi²-test or the Mann–Whitney U-Test for statistical significance using an alpha of 0.05.

Results

Patient baseline characteristics

A total of 102 patients, 43 of them women (42.2%) with a mean age of 71.4 ± 11.4 for men and 75.9 ± 14.0 years for women, (p = 0.015 for gender difference) were included. The mean APACHE-II score was 14. Roughly half of the patients were pre-treated with aspirin (47.1%), 18.6% with oral anticoagulation, 13.7% with clopidogrel and 6.9% with any kind of heparin. Further patient characteristics and risk factors are listed in Table 2.

DVT and PE incidence

A previously unknown thrombosis was detected in 8 patients (7.8%), 2 in women and 6 in men. Thrombus location was femoropopliteal in 5 patients, iliacal in 2 and at peroneal confluens in 1 patient. In five out of the eight DVT patients pulmonary embolism (PE) was detected upon CT lung scan (62.5% of DVT patients, 4.9% of all
patients). All PE’s were found in patients with a DVT above the knee, twice iliacal and femoropopliteal. Mean APACHE-II-Score of patients without DVT was 14.56, with DVT 14.38, which was slightly, but statistically not different. Two DVT patients had APACHE-II-Scores of 10 and 11 respectively, the other DVT patients scores of 15, 17, 20 and 21 respectively.

Risk factors and laboratory values in patients with and without DVT

The following established risk factors for VTE were tested: 1) smoking status, 2) immobility, 3) exsiccosis, 4) diabetes mellitus, 5) coagulation disorders, 6) renal insufficiency (Table 3). While there was a nominally increased relative risk in those with smoking (RR 3.40), immobility (RR 2.50),

---

**Table 1 APACHE II Scoring**

| Acute physiologic score | Aberration upwards | Aberration downwards |
|-------------------------|--------------------|---------------------|
| Points                  | +4                 | +3                  | +2                  | +1                  | 0                   | +1                  | +2                  | +3                  | +4                  |
| Temperature °C          | ≥ 41               | 39 - 40.9           | 38.5 - 38.9         | 36 - 38.4           | 34 - 35.9           | 32 - 33.9           | 30 - 31.9           | ≤ 29.9              |
| MAP mmHg                | ≥ 160              | 130 - 159           | 110 - 129           | 70 - 109            | 50 - 69             | ≤ 49                |
| Heart rate/min          | ≥ 180              | 140 - 179           | 110 - 139           | 70 - 109            | 55 - 69             | 40 - 54             | ≤ 39                |
| Resp. rate/min          | ≥ 50               | 35 - 49             | 25 - 34             | 12 - 24             | 10 - 11             | 6 - 9               | ≤ 5                 |
| Oxygenation             | ≥ 500              | 350 - 499           | 200 - 349           | < 200               | > 70                | 61 - 70             | 55 - 60             | ≤ 55                |
| Arterial pH             | ≥ 7.7              | 7.6 - 7.69          | 7.5 - 7.59          | 7.33 - 7.49         | 7.25 - 7.32         | 7.15 - 7.24         | < 7.15              |
| Sodium                  | ≥ 180              | 160 - 179           | 155 - 159           | 150 - 154           | 130 - 149           | 120 - 129           | 111 - 119           | ≤ 110               |
| Potassium               | ≥ 7                | 6.6 - 6.69          | 5.5 - 5.59          | 3.5 - 5.4           | 3.0 - 3.4           | 2.5 - 2.9           | ≤ 2.5               |
| Creatinine mg/dl        | ≥ 3.5              | 2.0 - 3.4           | 1.5 - 1.9           | 0.6 - 1.4           | < 0.6               | < 0.6               | < 0.6               |
| Hematocrit %            | ≥ 60               | 50 - 59.9           | 46 - 49.9           | 30 - 45.9           | 20 - 29.9           | < 20                |
| Leucocytes x10³         | ≥ 40               | 20 - 39.9           | 15 - 19.9           | 3 - 14.9            | 1 - 2.9             | < 1                 |

Glasgow Coma Scale (GCS)  
Points = 15 – actual GCS

| Age points | ≤ 44 | 45 - 54 | 55 - 64 | 65 - 74 | ≥ 75 |
|------------|------|---------|---------|---------|------|
| Points     | 0    | 2       | 3       | 5       | 6    |
Table 2 Patient characteristics and risk factor prevalence in patients with and without DVT

| Risk factors                  | Total (n = 102) | DVT (+) (n = 8) | DVT (−) (n = 94) |
|------------------------------|-----------------|-----------------|------------------|
| Male gender (n, %)           | 59 (57.8)       | 6 (75.0)        | 53 (56.4)        |
| ASA (n, %)                   | 48 (47.1)       | 3 (37.5)        | 45 (47.9)        |
| Clopidogrel (n, %)           | 14 (13.7)       | 0               | 14 (17.9)        |
| Marcumar (n, %)              | 19 (18.6)       | 0               | 19 (20.2)        |
| Heparin (n, %)               | 7 (6.9)         | 1 (12.5)        | 6 (6.4)          |
| Heart failure NYHA ≥ II      | 68 (66.7)       | 0               | 68 (72.3)        |
| Smoker (n, %)                | 15 (14.7)       | 3 (37.5)        | 12 (12.8)        |
| Immobility* (n, %)           | 54 (52.9)       | 6 (75.0)        | 48 (51.1)        |
| Compressions stockings       | 14 (13.7)       | 1 (12.5)        | 13 (13.8)        |
| Venous insufficiency (n, %)  | 30 (29.4)       | 1 (12.5)        | 29 (30.9)        |
| Renal insufficiency (n, %)   | 56 (54.9)       | 3 (37.5)        | 53 (56.4)        |
| Malignancy (n, %)            | 10 (9.8)        | 1 (12.5)        | 9 (9.6)          |
| Eosinosis (n, %)             | 21 (20.6)       | 2 (25.0)        | 19 (20.2)        |
| Diabetes mellitus (n, %)     | 38 (37.3)       | 3 (37.5)        | 35 (37.2)        |

Legend: *Immobility was defined as not able to leave the room but to visit toilet and bath in the room for more than 24 hours before hospital admission, n, number; SD, standard deviation.

exsiccosis (RR 12.9) and diabetes (RR 1.20) and a decreased risk in those with renal insufficiency (RR 0.49), confidence intervals were too wide and only smoking became borderline significant (p = 0.06).

The following laboratory values were tested: D-dimere, leucocytes, C-reactive protein (CRP), partial thromboplastin time (PTT), fibrinogen, thrombocytes, erythrocytes, quick, creatinin. No significant correlation was found for any of the named laboratory values. The highest risk ratios were found for D-dimere (RR 3.49), CRP (RR 1.97) and leucocytes (RR 1.95).

Clinical follow up
6 out of 8 DVT patients (75%) were transferred from the ICU to a general ward within a week after admission. One DVT patient stayed at the intensive care unit for 14 days and 1 patient died due to sepsis.

Discussion
The present prospective analysis is the first to report the prevalence of DVT in acutely admitted non-surgical intensive care unit patients in Germany. We investigated the isolated prevalence rate within 24 hours after hospital admission not considering DVT incidence rates during the ICU stay. We found a DVT prevalence of 7.8% with two thirds of the DVT positive patients presenting additional pulmonary embolism. The data are limited however by the patient number that was found to be too low to conduct a proper predictor analysis. This calls for a larger prospective survey to be conducted in this high risk patient group.

Prevalence of deep venous thrombosis
Limited data are available comparing VTE prevalence in critical ill medical patients admitted to non-surgical intensive care units with a variety of diseases, but not mechanically ventilated. Nevertheless these patients are frequent and show an increased mortality risk. In general medical units Lawall et al. [21] found in not critically ill patients a prevalence of 2.6% in medical patients, and Cheng [22] in a very similar patient population a prevalence of 1.7%. Oger et al. [23] reported (within 48 hours of hospital admission, including incidence during hospitalization, without suspected VTE at admission) an incidence of 5.5% (95% CI 3.1-9.5) asymptomatic DVT using compression ultrasound and 17.8% (95% CI 0.0-12.7) among patients over 80 years. A review by Crowther and Cook comprised data of several studies and found DVT in 5 – 10% of critically ill patients even if they receive unfractionated heparin for prophylaxis [24]. The majority appeared clinically silent, a known phenomenon from earlier studies [25-27]. One prospective cohort study of twice weekly ultrasounds identified proximal DVT during ICU stay in 25 out of 261 (9.6%) patients [28]. The PROTECT trial tested dalteparin versus unfractionated heparin and found at intensive care unit patients with a mean APACHE-II-Score of 21.5 a prevalence during ICU stay of 5.5% [29]. This number represents a cumulative prevalence and incidence in patients with ongoing thromboprophylaxis. Hong et al. prospectively screened 90 ICU patients without prophylaxis and repeated admission ultrasound 5–7 days after admission and 11.1% of patients developed DVT [30]. Sud et al. [13] compared ultrasound...
screening versus clinically suspected DVT case finding in medical-surgical ICU patients and found 85 proximal DVT’s per 1000 patients. These numbers are comparable to our findings.

Wells et al. found a high rate of false positive results with careful clinical assessment for DVT only or in combination with inflammation markers. They concluded that this approach for DVT screening is not useful in this patient group alone [31].

Older data reported by Hirsch et al. [25] for medical ICU patients reported a DVT prevalence of 33%, but this number included 8 months follow-up with ultrasound screenings after discharge from MICU.

Prevalence of pulmonary embolism

We found accompanying pulmonary embolism (PE) in 5 patients (62.5% of DVT patients, 4.9% of all patients). This rate is higher than in the literature described. There are data showing silent PE in around 33% of DVT patients for instance in the previously mentioned study by Lawall et al. in internal medicine and in a recent study by Tzoran et al., who found in 33% of DVT patients additional PE [32]. But those patients were no ICU patients, which are at higher risk for DVT than general medical ward patients. A large prospective multicenter Chinese trial found a prevalence of DVT during medical ICU stay including a 90 day follow up ultrasound and clinical examination of 7.3% with additional PE in 0.5% and isolated PE in 2.1% [33]. Berlot et al. retrospectively reviewed 600 autopsies and clinical data of all patients who died at a mixed surgical and medical ICU between 1996 and 2007 [34]. All patients received prophylaxis with subcutaneous low-molecular weight heparin. They found 13 confirmed PE, 20 not confirmed and 73 PE’s only discovered at the autopsy. The overall incidence was 14.3%. Among all non-surgical co-morbidities the presence of acute renal failure was associated with a higher risk of missed diagnoses, which was also found with a higher frequency in cases of septic shock.

Predictors of deep venous thrombosis

Several risk factors have been shown to be associated with DVT. We found a tendency towards an increased DVT risk for smoker, immobile, exsiccotic and diabetic patients, but none reaching statistical significance. No correlation was found in our study population for the established risk factors age and gender or for laboratory values. D-Dimer, leucocytes and CRP values showed a tendency towards an increased risk. Unfortunately those values are often increased anyway at hospital admission resulting from the primary admission diagnosis. They represent an ongoing unspecified inflammation process, which is common in this patient population also without a present DVT. A clinical use as DVT predicting risk factor cannot be deduced from those results. No correlation between DVT prevalence and a high APACHE-II-Score was found, but the incidence of DVT is quiet low for interpretation of statistical correlations.

Limitations

The patient group under investigation reflects a heterogeneous medical patient group with a wide range of differing thromboembolic risk constellations, predominantly acute cardiovascular and pulmonary disorders without the need for mechanical ventilation. The strength of the study is to have searched for predictors characterizing thromboembolic risk in these patients, who are frequently treated at ICUs but not extensively studied so far regarding thrombosis prevalence. As the patient numbers and resulting DVT/PE prevalence rates were too low, no significant predictors were identified. A larger survey with higher numbers of DVT and PE patients is clearly needed to allow a better patient characterisation using easy – available clinical signs and laboratory values.

Conclusions

Our results show a rather high asymptomatic DVT prevalence in acutely ill medical ICU admitted patients with APACHE-II-score > 10 and a considerable amount of accompanying pulmonary embolism. The studied patient group nonetheless lacks clear thromboembolic risk characterisation as conventional risk factors, laboratory values or the value of the APACHE-II-score seem to be not sufficient. This result calls for further investigation of a larger cohort of this special patient group. As long as data are missing physicians in this clinical setting should be aware of thromboembolic complications and consider a general DVT screening at hospital admission for this patient population.

Competing interests

The authors report no conflict of interests.

Authors’ contributions

All authors made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data. HL and CD designed the study, RA acquired the data, CZ and PB analysed the data and drafted the manuscript. The other authors revised the manuscript for important intellectual content and all authors granted final approval of the manuscript to be published.

Acknowledgements

The authors acknowledge the cooperation and commitment of all investigators and their staff, who contributed to the trial conduct.

Author details

1Department of Angiology, Asklepios Westklinikum Hamburg, Suurheid 20, 22559 Hamburg, Germany. 2Department of Angiology, Klinikum Karlsbad – Langensteinbach, Karlsbad, Germany. 3Institut für Pharmakologie und präventive Medizin, Mahlow, Germany. 4Krankenhaus Friedrichstadt, Medizinische Klinik II, Dresden, Germany.

Received: 10 January 2014 Accepted: 20 June 2014 Published: 5 July 2014
References

1. Guyatt GH, Akbar AN, Crowther M, Gateman DD, Schunemann HJ, American College of Chest Physicians Antithrombotic T, Prevention of Thrombosis P: Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):7S–47S.

2. Pandey A, Patnaik N, Singh M, Guleria R: Assessment of risk and prophylaxis for deep vein thrombosis and pulmonary embolism in medically ill patients during their early days of hospital stay at a tertiary care center in a developing country. Vasc Health Risk Manag 2009, 5:643–648.

3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J: Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007, 5(4):692–699.

4. Fowles JF, Price JF, Fowles FG: Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003, 25(1):1–5.

5. Cunningham RS: The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis. Semin Oncol 2006, 33(2 Suppl 4):S17–S25, quiz S41–S42.

6. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon M, Mittmann N, Cook DJ, Geerts W, Chan B, Dodek P, Gould MK, Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong 12. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong 11. Xu XF, Yang YH, Zhai ZG, Liu S, Zhu GF, Li CS, Wang C: Prevalence and incidence of deep venous thrombosis among patients in medical intensive care unit. Zonghua li xing bingtong yue za zhi 2008, 29(10):1034–1037.

7. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong BH, Zott RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, IMPROVE Investigators: Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011, 140(3):706–714.

8. Sow S, Mittram N, Cook DJ, Geerts W, Chan B, Dodek P, Gould MK, Guyatt G, Arabi Y, Fowler RA: Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Respir Crit Care Med 2011, 184(11):1289–1298.

9. Parikh KC, Oh D, Stittpunt C, Kalim H, Ullah S, Aggarwal SK: Venous thromboembolism prophylaxis in medical ICU patients in Asia (VOICE Asia): a multicenter, observational, cross-sectional study. Thromb Res 2012, 129(4):152–158.

10. Samarna MM, Dahl OE, Quinlan DJ, Mismetti P, Rosener N: Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haemostology 2003, 88(12):1410–1421.

11. Howell MD, Gersch JM, Knowlton A: Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case–control study. J Clin Epidemiol 2001, 54(8):810–816.

12. Hull RD, Schellong SM, Tapson VF, Monreal M, Samarna MM, Turpie AG, Wildgoose P, Yusen RD: Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 2006, 22(1):31–38.

13. Kraus WA, Zimmerman JF, Wagner DP, Draper EA, Lawrence DE: APACHE–acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981, 9(5):591–597.

14. Kraus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13(10):818–829.

15. Markgraf R, Deutschmann G, Plentka L, Scholten T, Lorenz C: Performance of the score systems Acute Physiology and Chronic Health Evaluation II and III at an interdisciplinary intensive care unit, after customization. Crit Care 2001, 5(1):31–36.

16. Lawall H, Hoffmanns W, Hoffmanns P, Rapp U, Ames MA, Pira A, Paar WD, Bramlage P, Diehm C: Prevalence of deep vein thrombosis (DVT) in non-surgical patients at hospital admission. Thromb Haemost 2007, 98(4):765–770.

17. Cheng G, Chan C, Liu YT, Choy YF, Wong MM, Yeung PK, Ng KL, Tsang LS, Wong RS: Incidence of Deep Vein Thrombosis in Hospitalized Chinese Medical Patients and the Impact of DVT Prophylaxis. Thrombosis 2011, 2011:629383.

18. Oger E, Bressollette L, Nonent M, Lacut K, Guias B, Coutraud F, Leroyer C, Motier D: High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002, 88(4):592–597.

19. Crowther MA, Cook DJ: Thromboprophylaxis in medical-surgical critically ill patients. Curr Opin Crit Care 2008, 14(5):520–523.

20. Hinch DR, Ingento EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995, 273(15):1556–1571.

21. Marik PE, Andrews L, Maini B: The incidence of deep venous thrombosis in ICU patients. Chest 1997, 111(3):661–664.

22. Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Heibert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M, Canadian Critical Care Trials Group: Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 2008, 12(2):R28.

23. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G: Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005, 33(2):1565–1571.

24. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Valliance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE: Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011, 364(14):1305–1314.

25. Hong KC, Kim HI, Kim JY, Kwak KS, Cho OM, Cha HY, Lim SH, Song YJ: Risk factors and incidence of deep vein thrombosis in lower extremities among critically ill patients. J Clin Nurs 2012, 21(13–14):1840–1846.

26. Wells PS: Integrated strategies for the diagnosis of venous thromboembolism. J Thromb Haemost 2007, 5(Suppl 1):41–50.

27. Tizon S, Salvario G, Brenner B, Deixart D, Roman P, Visana A, Jimenez M, Monreal M: Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. J Thromb Haemost 2012, 10(4):564–571.

28. Li X, Fan J, Cheng YQ, Wang Y, Yao C, Zhong NS: Incidence and prevention of venous thromboembolism in acutely ill hospitalized elderly Chinese. Chin Med J 2011, 124(3):335–340.

29. Bertoc G, Calderen C, Vergolin A, Banchi M, Viviani M, Bussani R, Torelli L, Lucangelo U: Pulmonary embolism in critically ill patients receiving antithrombotic prophylaxis: a clinical-pathologic study. J Crit Care 2011, 26(1):28–33.

doi:10.1186/1756-0500-7-431
Cite this article as: Lawall et al.: Prevalence of deep vein thrombosis in acutely admitted ambulatory non-intensive surgical critical care unit patients. BMC Research Notes 2014 7:431.